Lamivudine (KAISER FOUNDATION HOSPITALS)
Welcome to the PulseAid listing for the Lamivudine drug offered from KAISER FOUNDATION HOSPITALS. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | KAISER FOUNDATION HOSPITALS |
| NON-PROPRIETARY NAME: | Lamivudine |
| SUBSTANCE NAME: | LAMIVUDINE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2014-05-29 |
| END MARKETING DATE: | 0000-00-00 |
Lamivudine HUMAN PRESCRIPTION DRUG Details:
| Item Description | Lamivudine from KAISER FOUNDATION HOSPITALS |
| LABELER NAME: | KAISER FOUNDATION HOSPITALS |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100(mg/1) |
| START MARKETING DATE: | 2014-05-29 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0179-0152_2240bccc-9851-42bc-ba78-f8cf8f2ae82c |
| PRODUCT NDC: | 0179-0152 |
| APPLICATION NUMBER: | ANDA202941 |
Other LAMIVUDINE Pharmaceutical Manufacturers / Labelers:
